DNA-based vaccine against Leishmaniasis

 

Leishmaniasis is one of the infectious diseases known as zoonoses where the pathogens can be transmitted between animals and humans. The disease is most prevalent in regions with a sub-tropical or Mediterranean climate.

 

Parasites of the genus Leishmania are transmitted by sand flies. The World Health Organization (WHO) has classed leishmaniasis as an emerging disease (a disease with an increasing incidence in humans). Several multinational research programs have been set up to develop new, more effective therapeutic agents and vaccines.

 

As early as 2004, MOLOGEN successfully conducted a study on the preventive vaccination against leishmaniais in dogs. In 2006, the MIDGE-based vaccine was out-licensed to a leading pharmaceutical company in the USA for continuative development.

 

MOLOGEN is currently planning further research and development programs, including programs for the treatment and prevention of leishmaniasis infections in humans. Leishmaniasis is increasingly expanding its range in countries with rapidly growing populations, such as China and India. In March 2007, MOLOGEN obtained patent protection for its MIDGE-Th1 technology in China. The patent creates the legal and commercial foundation for MOLOGEN to develop innovative vaccines for this market that is rich in potential.

 

For further information related to this severe parasitic disease, we recommend to visit the following website(s):

 

  WHO, World Health Organization

  CDC, Centers for Disease Control

  World Organization for Animal Health

  www.medizin.de

 

MOLOGEN®, MIDGE® and dSLIM® are registered trademarks of MOLOGEN AG